

16 Oct 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: BMS buys Mirati; slow Q3 for biopharma M&A; Roche on its neuroscience strategy; Alexion talks about AstraZeneca integration; and Gilead on trial diversity.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 13 October 2023, including: [*Bristol Myers Squibb Company*](#) buys [*Mirati Therapeutics, Inc.*](#); slow Q3 for biopharma M&A; [*Roche Holding AG*](#) on its neuroscience strategy; [*Alexion Pharmaceuticals Inc.*](#) talks about [*AstraZeneca PLC*](#) integration; and [*Gilead Sciences, Inc.*](#) on trial diversity.

This and all our other podcasts are available on the Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*BMS Looks To Expand Its Oncology Reach With Mirati Buyout*](#)" - Scrip, 9 Oct, 2023.)

(Also see "[*Slow Q3 For Biopharma M&A Boosted By Biogen/Reata*](#)" - Scrip, 10 Oct, 2023.)

(Also see "[*Already Number One In Neuroscience, Roche Extends Ionis RNA Partnership To Tackle Alzheimer's And Huntington's*](#)" - Scrip, 11 Oct, 2023.)

(Also see "[*Alexion On Its AstraZeneca Integration And Growth Plan*](#)" - Scrip, 10 Oct, 2023.)

(Also see "[*How Gilead Did Trial Diversity Before It Was Cool*](#)" - Scrip, 6 Oct, 2023.)

[Click here to explore this interactive content online](#) 